Tag: investment
-
Longevity Science Group Spins-Off Biotech Start-Up
An organization funding research on extending the human life span by preventing age-related diseases is founding its first biotechnology company.
-
Neuro Disease Biotech Gains $61M in Early Funds
A developer of treatments for Alzheimer’s disease that seeks to improve the condition of the brain’s support cells is raising £48 million ($US 61 million) in its first venture round.
-
Infographic – Global Q3 Venture Funding Levels Off
Global venture investment dollars in the third quarter of 2023 rose somewhat from the previous quarter, but remained at about the same level for the past 12 months.
-
Biomanufacturing Company Gains $9.5M in Early Funds
A company offering a biomanufacturing process it says is more efficient and scalable than conventional bio-production methods is raising $9.5 million in its first venture round.
-
Industry-Academic Center to Boost Rare Disease Therapies
An alliance of academic labs and venture investors is starting a new research enterprise to speed development of treatments for rare diseases in the U.S. and U.K.
-
Infographic – Biotech Index Continues Downward Trend
The Nasdaq Biotechnology Index, an indicator of investor sentiment in an industry based on science, continued heading down during the third quarter of 2023.
-
Cardiac Tech Start-Up Partners with Mayo Clinic
A new company developing digital cardiac diagnostics is collaborating with the Mayo Clinic on early detection of coronary artery disease, a key trigger of heart attacks.
-
Infographic – Q2 Tech Merger Values Up, Deals Down
The value of mergers and acquisitions in the global technology sector rose for the first time in over a year in the second quarter of 2023, while M&A deal counts dropped somewhat.
-
University Start-Up Developing Inhaled Gene Therapies
A new company spun-off from a university lab consortium is advancing gene therapies delivered through the lungs to treat rare inherited respiratory diseases.
-
Autoimmune Neuro Disease Start-Up Raises $58M
A new company developing treatments for neurological and psychiatric diseases from aberrant immune system activity is raising $58 million in seed funds.